{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.267","value":"0.08"},{"groupId":"OG001","spread":"0.432","value":"0.09"}]}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.252","value":"0.07"},{"groupId":"OG001","spread":"0.283","value":"0.07"}]}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.252","value":"0.07"},{"groupId":"OG001","spread":"0.266","value":"0.08"}]}],"title":"Cycle 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"description":"DSN was defined as the number of days of severe neutropenia (ANC \\<0.5×10\\^9/L) from the first occurrence of ANC below the threshold.","dispersionType":"Standard Deviation","groups":[{"description":"At each cycle for 4 cycles, participants received SPI-2012 at a fixed dose of 13.2 mg/0.6 mL, \\[3.6 mg granulocyte colony-stimulating factor {G-CSF}\\] SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m\\^2 and cyclophosphamide 600 mg/m\\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.","id":"OG000","title":"(Arm 1): SPI-2012 and TC"},{"description":"At each cycle for 4 cycles, participants received pegfilgrastim 6 mg (6 mg/0.6 mL G-CSF) SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m\\^2 and cyclophosphamide 600 mg/m\\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.","id":"OG001","title":"(Arm 2): Pegfilgrastim and TC"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle = 21 days)","title":"Duration of Severe Neutropenia (DSN) in Cycles 2, 3 and 4","type":"SECONDARY","unitOfMeasure":"Days"}